Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding Ltd.    ROG   CH0012032048

Delayed Quote. Delayed  - 07/29 03:59:41 pm
246.6 CHF   +0.45%
06:30a ROCHE : oeuvre management assignment for the lighting of the cathedr..
07/28 ROCHE : Township adopts roche phase 1 redevelopment plan
07/28 ROCHE : emicizumab continued to show promising safety and efficacy p..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Roche Holding Ltd. : Roche purchases shares in tender offer for Anadys Pharmaceuticals

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/23/2011 | 07:15am CEST

Basel, 23 November 2011

Roche purchases shares in tender offer for Anadys Pharmaceuticals

Roche (SWX: ROG.VX; RO.S; OTCQX; RHHBY) today announced that its wholly owned subsidiary Bryce Acquisition Corporation has accepted for payment all shares validly tendered pursuant to its tender offer for all outstanding shares of common stock of Anadys Pharmaceuticals, Inc. (NASDAQ: ANDS) at $3.70 per share in cash.

As of the expiration of the tender offer, a total of approximately 54,532,568 shares of Anadys common stock were tendered and not withdrawn (including approximately 2,345,764  shares tendered by delivery of notices of guaranteed delivery), representing approximately 94% of Anadys's outstanding shares.

Roche intends to complete the acquisition of Anadys through a short-form merger without a vote or meeting of Anadys's shareholders. In the merger, all shares of Anadys not owned by Anadys, Roche or their respective wholly owned subsidiaries (other than shares as to which appraisal rights are validly exercised) will be converted into the right to receive the same cash consideration per share as was paid in the tender offer.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80,000 employees worldwide and invested over 9 billion Swiss francs in R&D. The Group posted sales of 47.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical Co., Ltd., Japan. For more information: www.roche.com.

Cautionary Statement Regarding Forward-Looking Statements

Some of the statements contained in this press release are forward-looking statements, including statements regarding the expected consummation of the acquisition, which involves a number of risks and uncertainties including the satisfaction of closing conditions for the acquisition such as regulatory approval for the transaction, the tender of a majority of the outstanding shares of common stock of Anadys and the possibility that the transaction will not be completed. These statements are based on our current expectations, assumptions, estimates and projections about our business and our industry, and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's results, levels of activity, performance or achievements to be materially different from any future statements. We generally identify these statements by words or phrases such as "believe," "anticipate," "expect," "intend," "plan," "will," "may," "should," "estimate," "predict," "potential," "continue," or the negative of such terms or other similar expressions. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results and the timing of events may differ materially from the results discussed in the forward-looking statements, and you should not place undue reliance on these statements. The information contained in this press release is as of November 23, 2011. We disclaim any intent or obligation to update any forward-looking statements as a result of developments occurring after the period covered by this report or otherwise.

Important Additional Information

This press release is for informational purposes only and does not constitute an offer to purchase or a solicitation of an offer to sell Anadys common stock. The tender offer is being made pursuant to a tender offer statement on Schedule TO (including the Offer to Purchase, Letter of Transmittal and other related tender offer materials) filed by Roche with the Securities and Exchange Commission (the "SEC") on October 25, 2011 [and subsequently amended]. These materials, as they may be further amended from time to time, contain important information, including the terms and conditions of the offer, that should be read carefully before any decision is made with respect to the tender offer. Investors and Anadys's stockholders can obtain a free copy of these materials and other documents filed by Roche with the SEC at the website maintained by the SEC at www.sec.gov. The tender offer materials may also be obtained for free by contacting the information agent for the tender offer, Mackenzie Partners at (212) 929-5500 (call collect) or (800) 322-2885 (toll-free) (USA).

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ROCHE HOLDING LTD.
06:30a ROCHE : oeuvre management assignment for the lighting of the cathedral our lady ..
07/28 Chugai and Galderma Announce Global License Agreement for Nemolizumab CIM331,..
07/28 ROCHE : Sources Sought Notice - 65-- Roche Diagnostics Corp Histology Supplies f..
07/28 ROCHE : Township adopts roche phase 1 redevelopment plan
07/28 ROCHE : emicizumab continued to show promising safety and efficacy profile in lo..
07/27DJExperimental Alzheimer's Drug Fails in Trial
07/27 GSK chases next biotech asthma drug with 175 million pounds J&J deal
07/27 ROCHE : Architectural, engineering and planning services
07/22 ROCHE : F. Hoffmann-La Roche Announces Half Year Results 2016
07/22 ROCHE : Diagnostics Operations Assigned Patent
More news
Sector news : Pharmaceuticals - NEC
02:26pDJMERCK : Revenue Rises on Cancer, Hepatitis Treatments
02:10pDJMERCK : Revenue Rises on Cancer, Hepatitis Treatments
10:54aDJSANOFI : Profit Down as Diabetes Drug Sales Slip--Update
08:56aDJSanofi Profit Down as Diabetes Drug Sales Slip
07:45aDJSANOFI : Profit Down as Diabetes Drug Sales Slip
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
07/28 BIOMARIN : Product Announcements Increase Long Term Potential And Price Target
07/28 Roche's hemophilia candidate emicizumab shows encouraging results in early-st..
07/25 RETIREMENT STRATEGY : 5 Pharmaceutical Dividends To Buy Here
07/22 Puma Files, And The Battle Begins
07/22 Biogen Needs To Fill Pipeline Or Rethink Strategy
Advertisement
Financials ( CHF)
Sales 2016 51 205 M
EBIT 2016 17 846 M
Net income 2016 11 515 M
Debt 2016 10 958 M
Yield 2016 3,47%
P/E ratio 2016 18,17
P/E ratio 2017 16,41
EV / Sales 2016 4,34x
EV / Sales 2017 4,03x
Capitalization 211 287 M
More Financials
Chart ROCHE HOLDING LTD.
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | ROG | CH0012032048 | 4-Traders
Full-screen chart
Technical analysis trends ROCHE HOLDING LTD.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 298  CHF
Spread / Average Target 21%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Daniel O'Day COO-Roche Pharmaceuticals Division
Roland Diggelmann COO-Roche Diagnostics Division
Alan Hippe Chief Financial & Information Technology Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.-9.99%215 597
JOHNSON & JOHNSON21.16%342 345
PFIZER INC.13.60%222 398
NOVARTIS AG-5.30%214 061
MERCK & CO., INC.10.62%161 736
BRISTOL-MYERS SQUIBB C..8.53%124 630
More Results